Literature DB >> 22108731

From risk factors to structural heart disease: the role of inflammation.

Andreas P Kalogeropoulos1, Vasiliki V Georgiopoulou, Javed Butler.   

Abstract

Elevated levels of circulating proinflammatory cytokines and adipokines have been repeatedly associated with increased risk for clinically manifest (Stage C) heart failure in large cohort studies. However, the role of low-grade, subclinical inflammatory activity in the transition from risk factors (Stage A heart failure) to structural heart disease (Stage B heart failure) is less well understood. Recent evidence suggests that chronic low-grade inflammatory activity is involved in most mechanisms underlying progression of structural heart disease, including ventricular remodeling after ischemic injury, response to pressure and volume overload, and myocardial fibrosis. Inflammation also contributes to progression of peripheral vascular changes. 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22108731     DOI: 10.1016/j.hfc.2011.08.002

Source DB:  PubMed          Journal:  Heart Fail Clin        ISSN: 1551-7136            Impact factor:   3.179


  16 in total

1.  Systemic inflammation is associated with myocardial fibrosis, diastolic dysfunction, and cardiac hypertrophy in patients with hypertrophic cardiomyopathy.

Authors:  Lu Fang; Andris H Ellims; Anna L Beale; Andrew J Taylor; Andrew Murphy; Anthony M Dart
Journal:  Am J Transl Res       Date:  2017-11-15       Impact factor: 4.060

Review 2.  Interleukin-18 as a therapeutic target in acute myocardial infarction and heart failure.

Authors:  Laura C O'Brien; Eleonora Mezzaroma; Benjamin W Van Tassell; Carlo Marchetti; Salvatore Carbone; Antonio Abbate; Stefano Toldo
Journal:  Mol Med       Date:  2014-06-12       Impact factor: 6.354

3.  Incident heart failure in relation to vascular disease: insights from the Health, Aging, and Body Composition Study.

Authors:  Hassan Khan; Andreas P Kalogeropoulos; Faiez Zannad; Catherine N Marti; Peter W F Wilson; Vasiliki V Georgiopoulou; Alka M Kanaya; Anne B Newman; Erik Schelbert; Tamara B Harris; Stephen Kritchevsky; Clyde Yancy; Mihai Gheorghiade; Gregg C Fonarow; Javed Butler
Journal:  Eur J Heart Fail       Date:  2014-02-27       Impact factor: 15.534

Review 4.  Prevalence and importance of comorbidities in patients with heart failure.

Authors:  Filippos K Triposkiadis; John Skoularigis
Journal:  Curr Heart Fail Rep       Date:  2012-12

Review 5.  Mechanisms and consequences of inflammatory signaling in the myocardium.

Authors:  Jihyun Ahn; Jaetaek Kim
Journal:  Curr Hypertens Rep       Date:  2012-12       Impact factor: 5.369

Review 6.  Incorporating common biomarkers into the clinical management of heart failure.

Authors:  Meghana Halkar; W H Wilson Tang
Journal:  Curr Heart Fail Rep       Date:  2013-12

7.  Inflammatory stress exacerbates the progression of cardiac fibrosis in high-fat-fed apolipoprotein E knockout mice via endothelial-mesenchymal transition.

Authors:  Kun Ling Ma; Jing Liu; Jie Ni; Yang Zhang; Lin Li Lv; Ri Ning Tang; Hai Feng Ni; Xiong Zhong Ruan; Bi Cheng Liu
Journal:  Int J Med Sci       Date:  2013-02-28       Impact factor: 3.738

8.  Prescribing optimal nutrition and physical activity as "first-line" interventions for best practice management of chronic low-grade inflammation associated with osteoarthritis: evidence synthesis.

Authors:  Elizabeth Dean; Rasmus Gormsen Hansen
Journal:  Arthritis       Date:  2012-12-31

9.  Small intestinal permeability in older adults.

Authors:  Luzia Valentini; Sara Ramminger; Verena Haas; Elisa Postrach; Martina Werich; André Fischer; Michael Koller; Alexander Swidsinski; Stefan Bereswill; Herbert Lochs; Jörg-Dieter Schulzke
Journal:  Physiol Rep       Date:  2014-04-22

10.  LuQi Formula Regulates NLRP3 Inflammasome to Relieve Myocardial-Infarction-Induced Cardiac Remodeling in Mice.

Authors:  Xiaoqing Zhang; Dandan Zhao; Jiling Feng; Xiaoli Yang; Zhenzhen Lan; Tao Yang; Xiaoni Kong; Huiyan Qu; Hua Zhou
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.